Back to discover
Disease
Migraine, familial hemiplegic, 2
Late-stage therapeutic development
Also known as ATP1A2 familial or sporadic hemiplegic migraine, familial or sporadic hemiplegic migraine caused by mutation in ATP1A2, migraine, familial hemiplegic, type 2, FHM2+4 more
ATP1A2 familial or sporadic hemiplegic migraine, familial or sporadic hemiplegic migraine caused by mutation in ATP1A2, migraine, familial hemiplegic, type 2, FHM2, Mhp2, familial hemiplegic migraine type 2, hemiplegic migraine, familial type 2, migraine, familial basilar.
24
Clinical trials
1
Associated genes
1
Related proteins
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 6 clinical trials expected to report results, the earliest in Q1 2028.
Upcoming Milestones
- Q1 2028A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age.
- Q1 2029A Comparative Effectiveness Study of Oral Medications Used for Migraine Prevention: The APT Comparison Study
- Q1 2029Phase 3, Multicenter, Randomized, Double-blind, Group Sequential, Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age
- Q3 2030Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age
- Q1 2031A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age
Major developments
Upcoming trial readoutHigh impact
Results expected Q1 20282026-10-06
Upcoming trial readoutHigh impact
Results expected Q1 20312026-09-03
Clinical MilestonesView all 13Hide
Results posted
Results expected
- 2026-10-06A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age.Results expected Q1 2028
- 2026-09-03A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of AgeResults expected Q1 2031
- 2026-08-24A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 Years of AgeResults expected Q4 2031
- 2026-08-14Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of AgeResults expected Q3 2030
- 2026-08-14Phase 3, Multicenter, Randomized, Double-blind, Group Sequential, Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of AgeResults expected Q1 2029
Recently completed
- 2026-09-02Interventional, Open-label Trial, Investigating the Effectiveness of Eptinezumab in Participants With Migraine and Previous Inadequate Response to CGRP-targeting TherapiesCompleted
- 2026-08-11Randomized, Double-blind, Placebo-Controlled, Multiple-Attack Study With an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerability, and the Consistency of Effect of Atogepant for the Acute Treatment of Migraine (ECLIPSE)Completed
- 2026-07-13A Single Center, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Fremanezumab (675 mg Quarterly) in Female Patients Aged 18-45 With Menstrual MigraineCompleted
- 2026-06-13Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic MigraineCompleted
Other updates
- 2026-02-04A Prospective, Open-Label Study Examining the Use of Rimegepant ODT 75 mg or Zavegepant Nasal Spray 10 mg for Acute Treatment of Migraine in the Emergency Department SettingTerminated
- 2025-12-04A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2Terminated
+5 more in the activity timeline below
Activity timeline13
- 2026-10-06ClinicalA Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age.Results expected Q1 2028
- 2026-09-03ClinicalA Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of AgeResults expected Q1 2031
- 2026-09-02ClinicalInterventional, Open-label Trial, Investigating the Effectiveness of Eptinezumab in Participants With Migraine and Previous Inadequate Response to CGRP-targeting TherapiesCompleted
- 2026-08-24ClinicalA Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 Years of AgeResults expected Q4 2031
- 2026-08-14ClinicalPhase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of AgeResults expected Q3 2030
- 2026-08-14ClinicalPhase 3, Multicenter, Randomized, Double-blind, Group Sequential, Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of AgeResults expected Q1 2029
- 2026-08-11ClinicalRandomized, Double-blind, Placebo-Controlled, Multiple-Attack Study With an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerability, and the Consistency of Effect of Atogepant for the Acute Treatment of Migraine (ECLIPSE)Completed
- 2026-07-30ClinicalA Comparative Effectiveness Study of Oral Medications Used for Migraine Prevention: The APT Comparison StudyResults expected Q1 2029
- 2026-07-13ClinicalA Single Center, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Fremanezumab (675 mg Quarterly) in Female Patients Aged 18-45 With Menstrual MigraineCompleted
- 2026-06-16ClinicalA Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic MigraineResults posted
Clinical trials
The current development programme across all trial phases.
Clinical programme
24
6
18
6
Late-stage studies
Recruiting
Recently completed
Evidence coverage
How much of this condition's readable clinical evidence the confidence engine has incorporated, across its most-studied treatments. This measures coverage of the evidence base — not whether any treatment works.
High evidence coverage
Largest gap: no meaningful change (2, trial-readability).
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
Synonyms
ATP1A2 familial or sporadic hemiplegic migraine, familial or sporadic hemiplegic migraine caused by mutation in ATP1A2, migraine, familial hemiplegic, type 2, FHM2, Mhp2, familial hemiplegic migraine type 2, hemiplegic migraine, familial type 2, migraine, familial basilar
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Related entities are derived from literature co-mention (studied together) — associative, not causal.